Changes in US stocks | Omvoh's Phase III trial for pediatric ulcerative colitis was successful, Lilly (LLY.US) rose more than 5%, and its stock price reached a record high

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that on Tuesday, LLY.US (LLY.US) rose more than 5% to $1309.39, and its stock price reached a record high. According to the news, on October 19, Eli Lilly announced that the phase 3 ShinE-2 study on OmvoH treatment of children with ulcerative colitis had reached the main end; of 52 patients aged 6 to 17 who had clinical responses to Omvoh, 50% achieved clinical remission in week 52. Omvoh has now been approved in the US to treat adult patients with active ulcerative colitis and Crohn's disease. The company plans to submit research results to global regulators seeking to expand the drug's indications.